Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2019 1
2020 2
2021 2
2022 2
2023 1
2024 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

8 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean montoya a (600 results)?
A community-based healthcare package combining testing and prevention tools, including pre-exposure prophylaxis (PrEP), immediate HIV treatment, management of hepatitis B virus, and sexual and reproductive health (SRH), targeting female sex workers (FSWs) in Côte d'Ivoire: the ANRS 12381 PRINCESSE project.
Becquet V, Nouaman M, Plazy M, Agoua A, Zébago C, Dao H, Montoyo A, Jary A, Coffie PA, Eholié S, Larmarange J; the ANRS 12381 PRINCESSE team. Becquet V, et al. Among authors: montoyo a. BMC Public Health. 2021 Dec 4;21(1):2214. doi: 10.1186/s12889-021-12235-0. BMC Public Health. 2021. PMID: 34863122 Free PMC article. Clinical Trial.
Cost-Utility Analysis of a Dolutegravir-Based Versus Low-Dose Efavirenz-Based Regimen for the Initial Treatment of HIV-Infected Patients in Cameroon (NAMSAL ANRS 12313 Trial).
Bousmah MA, Nishimwe ML, Tovar-Sanchez T, Lantche Wandji M, Mpoudi-Etame M, Maradan G, Omgba Bassega P, Varloteaux M, Montoyo A, Kouanfack C, Delaporte E, Boyer S; New Antiretroviral and Monitoring Strategies in HIV-infected Adults in Low-Income Countries (NAMSAL) ANRS 12313 Study Group. Bousmah MA, et al. Among authors: montoyo a. Pharmacoeconomics. 2021 Mar;39(3):331-343. doi: 10.1007/s40273-020-00987-3. Epub 2020 Dec 23. Pharmacoeconomics. 2021. PMID: 33355914 Free PMC article.
Dolutegravir-Based or Low-Dose Efavirenz-Based Regimen for the Treatment of HIV-1.
NAMSAL ANRS 12313 Study Group; Kouanfack C, Mpoudi-Etame M, Omgba Bassega P, Eymard-Duvernay S, Leroy S, Boyer S, Peeters M, Calmy A, Delaporte E. NAMSAL ANRS 12313 Study Group, et al. N Engl J Med. 2019 Aug 29;381(9):816-826. doi: 10.1056/NEJMoa1904340. Epub 2019 Jul 24. N Engl J Med. 2019. PMID: 31339676 Clinical Trial.
Improving Ebola virus disease outbreak control through targeted post-exposure prophylaxis.
Hoffmann Dahl E, Mbala P, Juchet S, Touré A, Montoyo A, Serra B, Kojan R, D'Ortenzio E, Blomberg B, Jaspard M. Hoffmann Dahl E, et al. Among authors: montoyo a. Lancet Glob Health. 2024 Oct;12(10):e1730-e1736. doi: 10.1016/S2214-109X(24)00255-9. Epub 2024 Sep 10. Lancet Glob Health. 2024. PMID: 39270687 Free article. Review.
Dolutegravir-based and low-dose efavirenz-based regimen for the initial treatment of HIV-1 infection (NAMSAL): week 96 results from a two-group, multicentre, randomised, open label, phase 3 non-inferiority trial in Cameroon.
Calmy A, Tovar Sanchez T, Kouanfack C, Mpoudi-Etame M, Leroy S, Perrineau S, Lantche Wandji M, Tetsa Tata D, Omgba Bassega P, Abong Bwenda T, Varloteaux M, Tongo M, Mpoudi-Ngolé E, Montoyo A, Mercier N, LeMoing V, Peeters M, Reynes J, Delaporte E; New Antiretroviral and Monitoring Strategies in HIV-infected Adults in Low-Income Countries (NAMSAL) ANRS 12313 Study Group. Calmy A, et al. Among authors: montoyo a. Lancet HIV. 2020 Oct;7(10):e677-e687. doi: 10.1016/S2352-3018(20)30238-1. Lancet HIV. 2020. PMID: 33010241 Clinical Trial.
HIV stigma limits the effectiveness of PMTCT in Guinea: the ANRS 12344-DIAVINA study.
Breton G, Diallo OH, Cissé M, Diallo OH, Diallo NA, Soumaoro SA, Camara Y, Montoyo A, Rouzioux C, Koita Y, Peytavin G, Tubiana R, Frange P; ANRS 12344-DIAVINA study group. Breton G, et al. Among authors: montoyo a. J Antimicrob Chemother. 2022 Oct 28;77(11):3093-3101. doi: 10.1093/jac/dkac287. J Antimicrob Chemother. 2022. PMID: 36031792 Free PMC article.
Durability of the Efficacy and Safety of Dolutegravir-Based and Low-Dose Efavirenz-Based Regimens for the Initial Treatment of Human Immunodeficiency Virus Type 1 Infection in Cameroon: Week 192 Data of the NAMSAL-ANRS-12313 Study.
Mpoudi-Etame M, Tovar Sanchez T, Bousmah MA, Omgba Bassega P, Olinga J, Mimbe E, Foalem M, Chiep C, Edimo S, Varloteaux M, Pelloquin R, Lamare N, Boyer S, Peeters M, Reynes J, Calmy A, Hill A, Delaporte E, Kouanfack C; New Antiretroviral and Monitoring Strategies in HIV-infected Adults in Low-income countries (NAMSAL-ANRS-12313) study group. Mpoudi-Etame M, et al. Open Forum Infect Dis. 2023 Nov 20;10(12):ofad582. doi: 10.1093/ofid/ofad582. eCollection 2023 Dec. Open Forum Infect Dis. 2023. PMID: 38156046 Free PMC article.
Incidence of HIV infection and associated factors among female sex workers in Côte d'Ivoire, results of the ANRS 12361 PrEP-CI study using recent infection assays.
Nouaman MN, Becquet V, Plazy M, Coffie PA, Zébago C, Montoyo A, Anoma C, Eholié S, Dabis F, Larmarange J; ANRS 12361 PrEP-CI Study group. Nouaman MN, et al. Among authors: montoyo a. PLoS One. 2022 Nov 17;17(11):e0271988. doi: 10.1371/journal.pone.0271988. eCollection 2022. PLoS One. 2022. PMID: 36395099 Free PMC article.